Navigation Links
Moderate use averts failure of type 2 diabetes drugs in animal model
Date:10/27/2008

lternating periods of drug treatment with periods when the patient's symptoms are managed by insulin injection, Nichols suggests.

Type 2 diabetes accounts for 90 percent to 95 percent of the estimated 16 million Americans with diabetes. Patients with the disorder develop resistance to insulin, a hormone that helps the body control blood sugar levels. In many cases, their beta cells also make less insulin. Physicians typically treat the condition with a sulfonylurea and metformin, a drug that increases insulin sensitivity.

Sulfonylureas bind to potassium channels on the surfaces of beta cells. These channels normally control electrical activity and hence the levels of calcium in the cell; when the drug blocks the channels, calcium levels rise in the beta cell, causing release of insulin.

Nichols and Remedi saw an important opportunity to learn about the long-term failure of sulfonylureas with the availability of an implantable time-release capsule form of one of the drugs, glibenclamide. They implanted the capsules in the necks of mice. As expected, the drugs initially caused mouse beta cells to release more insulin and blood sugar levels dropped rapidly. Within a few days, though, the response to the drug reversed: Insulin secretion levels dropped, and blood sugar levels rose dramatically.

Examination of the pancreas showed that the animals' beta cells were still alive and contained normal levels of insulin.

"The problem seems to lie somewhere between the trigger for secreting insulin, which was hyperactivated while they were on the medication, and the actual mechanisms that release insulin," Nichols says. "The insulin is there, it's just not ready to release."

Nichols and Remedi are currently seeking further insight into the causes of this breakdown.


'/>"/>

Contact: Michael Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Moderate prenatal exposure to alcohol and stress in monkeys can cause touch sensitivity
2. Moderate quantities of dirt make more rain
3. High blood pressure, low energy -- a recipe for heart failure
4. Certain diseases, birth defects may be linked to failure of protein recycling system
5. Genetic variant mimics effect of heart failure medications
6. Many African-Americans have a gene that prolongs life after heart failure
7. Jefferson receives $11.6M NIH grant to study novel mechanisms of heart failure
8. Oocyte-specific gene mutations cause premature ovarian failure
9. Vitamin D: New way to treat heart failure?
10. Failure to bridle inflammation spurs atherosclerosis
11. Failure of the 1st attempt at assisted reproduction justifies at least 1 additional cycle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... by a combination of genetic and environmental factors. For ... external influences. According to scientists from the Max Planck ... not harmful bacteria that trigger multiple sclerosis, but ... every human being needs for digestion. The researchers ...
... -- On Friday, Oct. 28 2011 the research icebreaker ... 200 scientists and technicians from research institutions in 14 ... They will examine a wide variety of topics: oceanography ... bacteria, tiny algae and animals all the way to ...
... DIEGO (Oct.27, 2011) The La Jolla ... fifth organization in the prestigious Sanford Consortium for ... for Biological Studies, The Scripps Research Institute, University ... Research Institute in the first-of-its-kind multi-institutional stem cell ...
Cached Biology News:Natural intestinal flora involved in the emergence of multiple sclerosis 2Natural intestinal flora involved in the emergence of multiple sclerosis 3RV Polarstern launches 28th Antarctic season 2La Jolla Institute joins Sanford Consortium for Regenerative Medicine 2La Jolla Institute joins Sanford Consortium for Regenerative Medicine 3
(Date:5/21/2015)... PA (PRWEB) May 21, 2015 ... has joined the firm as senior statistician and Principal, ... years of experience in the management and analysis of ... pharmaceutical and chemical industries. , “We’re delighted to have ... capabilities in data analytics,” said Dr. Philippe Cini, Group ...
(Date:5/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ... Cell Therapy Market Outlook 2020 " report to ... tissue and regenerative medicine is expected to have huge ... could help in the growth of deregulated organs. Several ... are unable to form new tissue or sometimes organ ...
(Date:5/20/2015)... 20, 2015 Agricultural firm H.J. Baker ... its acquisition of Tiger-Sul. Since the purchase of ... Canada) in May 2005, H.J. Baker has leveraged the ... into a comprehensive portfolio of product offerings and solutions ... Baker and the innovation of Tiger-Sul, transforming the company ...
(Date:5/20/2015)... , May 20, 2015  Resolution Bioscience announced today ... ctDx ALK TM , a blood-based liquid biopsy for ... lung carcinoma (NSCLC), the most common form of this ... to guide patients to personalized therapies and direct them ... The Department of Health, the CLIA authority in ...
Breaking Biology Technology:Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2
... CALL DATE: Wednesday, Aug. 6, 2008 TIME: ... Dr. Candace Kendle, Chairman and CEO, ... call and,simultaneous webcast on Wednesday, Aug. 6 at 9:30 a.m. Eastern ... 30, 2008. A,question and answer session will follow., Webcast Instructions, ...
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced ... Daiichi Sankyo), has received marketing,approval from the Japanese ... label extension of Biopten(R) (sapropterin dihydrochloride), which,contains the ... for the,treatment of patients with phenylketonuria (PKU). BioMarin ...
... Consent Judgment Terminating Litigation --, MADISON, N.J., ... and,Impax Laboratories Inc. today announced that all conditions ... pertaining to Impax,s proposed,generic capsule formulation of Wyeth,s ... States District Court for the District of,Delaware. The ...
Cached Biology Technology:Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast 2Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 2Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 3Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 4Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit 2Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit 3
Request Info...
... are available in two product models - the ... models is that the 6000AT+ includes a membrane ... aerosol for improved detection limits and reduced oxides. ... range of elements by 10-40 times. Note that ...
... of RNase A-type ribonucleases Product Description: ,QIAGEN ... origin that binds noncovalently and inactivates a ... and C). It does not interfere with ... CL3. QIAGEN RNase Inhibitor inhibits greater than ...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
Biology Products: